Cutting edge techniques to treat chronic inflammatory conditions
Banksia BioPharm is the first of a new generation of Biotech Companies embracing the new world of Blockchain. A fantastic lead product combined with a new type of funding model makes Banksia truely unique.
Banksia’s BaRA Therapeutic for Rheumatoid Arthritis (RA) aims to address this debilitating condition in a new and more effective way. No doubt you or someone you know suffers from RA or other chronic inflammation disorder, and the pain and limitations it places in their lives.
Why reinvent the wheel? Mother nature has spent millions, if not billions of years perfecting anti-inflammation agents in a range of organisms. These anti-inflammation agents or ‘immuno-modulators’ can be harnessed, modified and even improved to treat disease.
Banksia aims to “Change the way we treat inflammation” and in doing so, we may very well change the way we do Biotech in a very positive way…
Suite 9, Ansuya Estate,
Revolution Avenue, Victoria,
Banksia BioPharm achieved a Five Star, 10/10 Rating with ICO Reviewer! Check out what they have to say about us through the link above. We are currently under review with 10 more sites like this, follow us on our social media channels to hear about the results.
Banksia’s BaRA Therapeutic for Rheumatoid Arthritis (RA) is nothing short of remarkable. Studies have shown that the native BaRA protein is ‘orders of magnitude’ more effective that the current market leaders. Read about it here.
The Rheumatoid Arthritis market has been projected to reach US$80.7 Billion by 2020. Current leading therapies in this space have significant shortcomings, not the least of which is a tendency for their users to become immune to their effects. Learn more about the RA market in our whitepaper.
WORLD CLASS TEAM
We have an experienced and passionate team. A key member of that team is Dr Goran Ando, former Chairman of Novo Nordisk A/S. Dr Ando’s involvement should speak volumes about the quality and potentiality of Banksia BioPharm. Learn more about the team here.
Achieving a solid Royalty Deal with a Large Pharmaceutical Company is a cornerstone of our approach. Our team has pre-existing relationships with key Pharma decision makers and influencers. When the time is right, Banksia will have access to the right people to make a Royalty Deal a reality.
UNIQUE FUNDING MODEL
Banksia BioPharm is the first Biotech Company to boldly enter the world of Blockchain and fund itself through a ‘first of a kind’ Security Tokenization of its Lead Product’s future royalty stream. To learn more visit our investors tab or read about it in detail in our whitepaper.
CHANGING THE WORLD
A bold statement? Banksia will change the way we treat inflammation. In doing so we will also change the way we do Biotech. This new Biotech funding model when more widely adopted, could fuel a new age of Biomedical advancements that could quite literally change the world.
Use the form below to contact us regarding your enquiry, and please be as detailed as possible.